CMB 305

Drug Profile

CMB 305

Alternative Names: CMB-305; ID-CMB305; LV 305 + G 305

Latest Information Update: 11 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immune Design
  • Developer Genentech; Immune Design
  • Class Cancer vaccines; Peptide vaccines; Peptides; RNA; RNA vaccines
  • Mechanism of Action Dendritic cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Soft tissue sarcoma
  • Phase I Solid tumours

Most Recent Events

  • 16 Oct 2017 Immune Design plans a phase III trial for Soft tissue sarcoma (Late-stage disease, Metastatic disease, Unresectable/Inoperable, Monotherapy) in USA in mid-2018
  • 08 Sep 2017 Updated efficacy, immunogenicity and safety data from a phase II trial in Soft tissue sarcoma presented at the European Society of Medical Oncology (ESMO-2017)
  • 30 Aug 2017 Efficacy and immunogenicity data from a phase II trial in Soft tissue sarcoma released by Immune Design
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top